Related references
Note: Only part of the references are listed.Extracellular vesicles increase the enzymatic activity of lysosomal proteins and improve the efficacy of enzyme replacement therapy in Fabry disease
Bane Abasolo et al.
MOLECULAR GENETICS AND METABOLISM (2020)
Bacterial Inclusion Bodies: A Treasure Trove of Bioactive Proteins
Priyank Singhvi et al.
TRENDS IN BIOTECHNOLOGY (2020)
Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice
Julie C. Ullman et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before and After 18 Years of Age
Rossella Parini et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2020)
The New York pilot newborn screening program for lysosomal storage diseases: Report of the First 65,000 Infants
Melissa P. Wasserstein et al.
GENETICS IN MEDICINE (2019)
Pharmacokinetics, pharmacodynamics, and safety of moss-aGalactosidase A in patients with Fabry disease
Julia B. Hennermann et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2019)
Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial
Raphael Schiffmann et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2019)
FACTs Fabry gene therapy clinical trial: Two-year data
Jeffrey A. Medin et al.
MOLECULAR GENETICS AND METABOLISM (2019)
Targeted nanoliposomes for the treatment of Fabry disease
[Anonymous]
MOLECULAR GENETICS AND METABOLISM (2019)
Exosome-mediated delivery of active glucocerebrosidase to Gaucher model cells
Hojun Choi et al.
MOLECULAR GENETICS AND METABOLISM (2019)
The glycosylation design space for recombinant lysosomal replacement enzymes produced in CHO cells
Weihua Tian et al.
NATURE COMMUNICATIONS (2019)
TPP1 Delivery to Lysosomes with Extracellular Vesicles and their Enhanced Brain Distribution in the Animal Model of Batten Disease
Matthew J. Haney et al.
ADVANCED HEALTHCARE MATERIALS (2019)
Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies
Mireia Pesarrodona et al.
ADVANCED SCIENCE (2019)
Targeted delivery of lysosomal enzymes to the endocytic compartment in human cells using engineered extracellular vesicles
Mai Anh Do et al.
SCIENTIFIC REPORTS (2019)
A Brief Reminder of Systems of Production and Chromatography-Based Recovery of Recombinant Protein Biopharmaceuticals
B. Owczarek et al.
BIOMED RESEARCH INTERNATIONAL (2019)
The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts
Dominique P. Germain et al.
MOLECULAR GENETICS AND METABOLISM REPORTS (2019)
Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy
Alberto B. Burlina et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2018)
Emptying the stores: lysosomal diseases and therapeutic strategies
Frances M. Platt
NATURE REVIEWS DRUG DISCOVERY (2018)
Release of targeted protein nanoparticles from functional bacterial amyloids: A death star-like approach
Ugutz Unzueta et al.
JOURNAL OF CONTROLLED RELEASE (2018)
A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II
Hiroyuki Sonoda et al.
MOLECULAR THERAPY (2018)
Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease
Malte Lenders et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Biopharmaceutical benchmarks 2018
Gary Walsh
NATURE BIOTECHNOLOGY (2018)
Lysosomal storage diseases
Frances M. Platt et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement
Nicolas Guerard et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Enzyme replacement therapies: what is the best option?
Azam Safary et al.
BIOIMPACTS (2018)
Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study
Derralynn A. Hughes et al.
JOURNAL OF MEDICAL GENETICS (2017)
Achieving the Promise of Therapeutic Extracellular Vesicles: The Devil is in Details of Therapeutic Loading
Dhruvitkumar S. Sutaria et al.
PHARMACEUTICAL RESEARCH (2017)
Bacterial Inclusion Bodies: Discovering Their Better Half
Ursula Rinas et al.
TRENDS IN BIOCHEMICAL SCIENCES (2017)
Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34+ Cells for Correction of Fabry Disease
Ju Huang et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2017)
Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives
Melani Solomon et al.
ADVANCED DRUG DELIVERY REVIEWS (2017)
Mannose receptor-mediated delivery of moss-made α-galactosidase A efficiently corrects enzyme deficiency in Fabry mice
Jin-Song Shen et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2016)
Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders
Marina I. Giannotti et al.
ACS APPLIED MATERIALS & INTERFACES (2016)
α-Galactosidase-A-Loaded Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration
Ingrid Cabrera et al.
ADVANCED HEALTHCARE MATERIALS (2016)
Strategies for the production of difficult-to-express full-length eukaryotic proteins using microbial cell factories: production of human alpha-galactosidase A
Ugutz Unzueta et al.
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY (2015)
A novel bio-functional material based on mammalian cell aggresomes
Escarlata Rodriguez-Carmona et al.
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY (2015)
Lysosomal Storage Disorder Screening Implementation: Findings from the First Six Months of Full Population Pilot Testing in Missouri
Patrick V. Hopkins et al.
JOURNAL OF PEDIATRICS (2015)
Characterization of a chemically modified plant cell culture expressed human α-Galactosidase-A enzyme for treatment of Fabry disease
Tali Kizhner et al.
MOLECULAR GENETICS AND METABOLISM (2015)
Polymer Capsules as a Theranostic Tool for a Universal In Vitro Screening Assay-The Case of Lysosomal Storage Diseases
Moritz Nazarenus et al.
PARTICLE & PARTICLE SYSTEMS CHARACTERIZATION (2015)
Carboxyl-Terminal Truncations Alter the Activity of the Human α-Galactosidase A
Mariam Meghdari et al.
PLOS ONE (2015)
The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders.
K Wyatt et al.
HEALTH TECHNOLOGY ASSESSMENT (2014)
Enhancing Biodistribution of Therapeutic Enzymes In Vivo by Modulating Surface Coating and Concentration of ICAM-1-Targeted Nanocarriers
Janet Hsu et al.
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY (2014)
Enzyme Replacement Therapy Attenuates Disease Progression in a Canine Model of Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)
Martin L. Katz et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2014)
Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics
Jose Luis Corchero et al.
BIOTECHNOLOGY ADVANCES (2013)
Extracellular vesicles: Exosomes, microvesicles, and friends
Graca Raposo et al.
JOURNAL OF CELL BIOLOGY (2013)
Multifunctional Nanovesicle-Bioactive Conjugates Prepared by a One-Step Scalable Method Using CO2-Expanded Solvents
Ingrid Cabrera et al.
NANO LETTERS (2013)
Specific Transfection of Inflamed Brain by Macrophages: A New Therapeutic Strategy for Neurodegenerative Diseases
Matthew J. Haney et al.
PLOS ONE (2013)
Production of active human glucocerebrosidase in seeds of Arabidopsis thaliana complex-glycan-deficient (cgl) plants
Xu He et al.
GLYCOBIOLOGY (2012)
CNS Penetration of Intrathecal-Lumbar Idursulfase in the Monkey, Dog and Mouse: Implications for Neurological Outcomes of Lysosomal Storage Disorder
Pericles Calias et al.
PLOS ONE (2012)
Long-Term Effect of Antibodies against Infused Alpha-Galactosidase A in Fabry Disease on Plasma and Urinary (lyso)Gb3 Reduction and Treatment Outcome
Saskia M. Rombach et al.
PLOS ONE (2012)
Recent advances in stealth coating of nanoparticle drug delivery systems
Zohreh Amoozgar et al.
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY (2012)
pH-Responsive Polysaccharide-Based Polyelectrolyte Complexes As Nanocarriers for Lysosomal Delivery of Therapeutic Proteins
Marina I. Giannotti et al.
BIOMACROMOLECULES (2011)
Integrated Approach to Produce a Recombinant, His-Tagged Human α-Galactosidase A in Mammalian Cells
Jose Luis Corchero et al.
BIOTECHNOLOGY PROGRESS (2011)
The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease
Suhrad G. Banugaria et al.
GENETICS IN MEDICINE (2011)
Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease
Janet Hsu et al.
JOURNAL OF CONTROLLED RELEASE (2011)
Biological activities of histidine-rich peptides; merging biotechnology and nanomedicine
Neus Ferrer-Miralles et al.
MICROBIAL CELL FACTORIES (2011)
Glycosylation of Therapeutic Proteins An Effective Strategy to Optimize Efficacy
Ricardo J. Sola et al.
BIODRUGS (2010)
Delivery of Therapeutic Proteins
Dipak S. Pisal et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2010)
Vasculopathy in patients with Fabry disease: Current controversies and research directions
S. M. Rombach et al.
MOLECULAR GENETICS AND METABOLISM (2010)
Fabry disease
Dominique P. Germain
ORPHANET JOURNAL OF RARE DISEASES (2010)
New biotechnological and nanomedicine strategies for treatment of lysosomal storage disorders
Silvia Muro
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY (2010)
Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha
Akemi Tanaka et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2010)
Glycan Engineering and Production of 'Humanized' Glycoprotein in Yeast Cells
Yasunori Chiba et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2009)
Glycosylation- and phosphorylation-dependent intracellular transport of lysosomal hydrolases
Sandra Pohl et al.
BIOLOGICAL CHEMISTRY (2009)
Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells
Jin-Song Shen et al.
MOLECULAR GENETICS AND METABOLISM (2008)
The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease
Joe T. R. Clarke et al.
GENETICS IN MEDICINE (2007)
α-galactosidase A in vascular disease
Peter F. Bodary et al.
TRENDS IN CARDIOVASCULAR MEDICINE (2007)
Enzyme therapy in mannose receptor-null mucopolysaccharidosis VII mice defines roles for the mannose 6-phosphate and mannose receptors
William S. Sly et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement
Christine M. Eng et al.
GENETICS IN MEDICINE (2006)
Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice
H Sakuraba et al.
JOURNAL OF HUMAN GENETICS (2006)
RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature
K Temming et al.
DRUG RESISTANCE UPDATES (2005)
Aggregation as bacterial inclusion bodies does not imply inactivation of enzymes and fluorescent proteins -: art. no. 27
E García-Fruitós et al.
MICROBIAL CELL FACTORIES (2005)
Recent advances with liposomes as pharmaceutical carriers
VP Torchilin
NATURE REVIEWS DRUG DISCOVERY (2005)
Recombinant human acid beta-glucosidase stored in tobacco seed is stable, active and taken up by human fibroblasts
S Reggi et al.
PLANT MOLECULAR BIOLOGY (2005)
The molecular defect leading to Fabry disease:: Structure of human α-galactosidase
SC Garman et al.
JOURNAL OF MOLECULAR BIOLOGY (2004)
Glycosylation-independent taraetina enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice
JH LeBowitz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Fabry disease: overall effects of agalsidase alfa treatment
M Beck et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2004)
The cell biology of lysosomal storage disorders
AH Futerman et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease
K Lee et al.
GLYCOBIOLOGY (2003)
Safety and efficacy of recombinant human α-galactosidase a replacement therapy in Fabry's disease.
CM Eng et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Aggresomes and Russell bodies - Symptoms of cellular indigestion?
RR Kopito et al.
EMBO REPORTS (2000)
Share Paper
